TY - JOUR
T1 - Subclinical acromegaly
T2 - to treat or not to treat?
AU - Shimon, Ilan
AU - Adnan, Zaina
AU - Hirsch, Dania
AU - Duskin-Bitan, Hadar
AU - Akirov, Amit
N1 - Publisher Copyright:
© The Japan Endocrine Society.
PY - 2022
Y1 - 2022
N2 - Patients with acromegaly usually present with the classical signs of acromegaly, whereas patients without the specific signs or symptoms are rarely diagnosed. This unique entity can be named “subclinical acromegaly”. This was a retrospective study. Our study group consisted of 6 patients (4 females) with incidentally diagnosed acromegaly, most following head MRI for unrelated reasons and without the specific signs of acromegaly. Mean age at diagnosis was 48.8 ± 19.2 years. Baseline IGF-1 ranged between 1.3–2.0 × upper limit of normal (ULN). MRI depicted a pituitary microadenoma in 5 patients, and one patient presented with a 12 mm intra-sellar macroadenoma. Mean calculated SAGIT clinical score was 4.8. Three patients underwent trans-sphenoidal resection; two achieved hormonal remission and one improved but did not normalize IGF-1 following surgery. Four patients (including one following surgery) were given somatostatin analogs, and three normalized IGF-1. Several patients improved clinically following treatment, reporting improvement in snoring, hypertension, or weight loss, and pituitary adenoma decreased in size in 2 patients that responded to medical treatment. We report a series of 6 patients with very mild and subclinical acromegaly. It is uncertain whether all such patients will gain clinical benefit from treatment, but most experienced clinical improvement due to treatment.
AB - Patients with acromegaly usually present with the classical signs of acromegaly, whereas patients without the specific signs or symptoms are rarely diagnosed. This unique entity can be named “subclinical acromegaly”. This was a retrospective study. Our study group consisted of 6 patients (4 females) with incidentally diagnosed acromegaly, most following head MRI for unrelated reasons and without the specific signs of acromegaly. Mean age at diagnosis was 48.8 ± 19.2 years. Baseline IGF-1 ranged between 1.3–2.0 × upper limit of normal (ULN). MRI depicted a pituitary microadenoma in 5 patients, and one patient presented with a 12 mm intra-sellar macroadenoma. Mean calculated SAGIT clinical score was 4.8. Three patients underwent trans-sphenoidal resection; two achieved hormonal remission and one improved but did not normalize IGF-1 following surgery. Four patients (including one following surgery) were given somatostatin analogs, and three normalized IGF-1. Several patients improved clinically following treatment, reporting improvement in snoring, hypertension, or weight loss, and pituitary adenoma decreased in size in 2 patients that responded to medical treatment. We report a series of 6 patients with very mild and subclinical acromegaly. It is uncertain whether all such patients will gain clinical benefit from treatment, but most experienced clinical improvement due to treatment.
KW - Acromegaly
KW - Adenoma
KW - Insulin-like growth factor-1 (IGF-1)
KW - Subclinical
UR - http://www.scopus.com/inward/record.url?scp=85142624978&partnerID=8YFLogxK
U2 - 10.1507/endocrj.EJ22-0066
DO - 10.1507/endocrj.EJ22-0066
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35732439
AN - SCOPUS:85142624978
SN - 0918-8959
VL - 69
SP - 1323
EP - 1328
JO - Endocrine Journal
JF - Endocrine Journal
IS - 11
ER -